Logo

AbbVie's Orilissa (elagolix) Receives Health Canada Approval to Treat Moderate-to-Severe Pain Associated with Endometriosis

Share this
AbbVie's Orilissa (elagolix) Receives Health Canada Approval to Treat Moderate-to-Severe Pain Associated with Endometriosis

AbbVie's Orilissa (elagolix) Receives Health Canada Approval to Treat Moderate-to-Severe Pain Associated with Endometriosis

Shots:
  • The approval is based on two P-III studies assessing Orilissa 150 mg qd and 200 mg bid vs PBO enrolling 1-700 women with moderate to severe endometriosis pain
  • P-III studies Results: showed reduction in daily menstrual pain and non-menstrual pelvic pain @6mos.; reduction in numeric rating scale (NRS) scores @3mos.; reduction in pain during sexual intercourse @3mos.
  • Orilissa recommend doses 150mg qd and 200mg bid for up to 12mos is expected to be available in Canada from Nov'18
Click here to read full press release/ article | Ref: PRNewswire | Image: Barron

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

We Have a Viewership of 1,00,000 + Views

Join the PharmaShot Family